Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
68.84
+1.78 (2.65%)
At close: Dec 20, 2024, 4:00 PM
68.82
-0.02 (-0.03%)
After-hours: Dec 20, 2024, 4:36 PM EST
Incyte Employees
Incyte had 2,524 employees as of December 31, 2023. The number of employees increased by 200 or 8.61% compared to the previous year.
Employees
2,524
Change (1Y)
200
Growth (1Y)
8.61%
Revenue / Employee
$1,614,842
Profits / Employee
$12,869
Market Cap
13.26B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Tenet Healthcare | 106,500 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 27,048 |
Revvity | 11,500 |
BioMarin Pharmaceutical | 3,401 |
Genmab | 2,204 |
Neurocrine Biosciences | 1,400 |
INCY News
- 4 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 11 days ago - Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire
- 14 days ago - Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer - Business Wire
- 15 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 25 days ago - Incyte Announces Updated Presentation Time for Upcoming Investor Conference - Business Wire
- 26 days ago - Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting - Business Wire
- 4 weeks ago - Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Investopedia
- 4 weeks ago - Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock. - Barrons